Asfand Yar Cheema/LinkedIn
Sep 4, 2025, 22:00
Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Asfand Yar Cheema, Cleveland Clinic
Presents results from a PSM cohort study evaluating the association of GLP-1 agonist therapy and key clinical outcomes in Polycythemia Vera.
GLP-1 agonist therapy is associated with significantly reduced risks of all-cause mortality, myelofibrosis progression, VTE, healthcare utilization, AKI, and ischemic stroke/TIA.
Randomized controlled trials are required to confirm GLP-1 agonist safety and efficacy in PV.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Jun 16, 2026, 03:15Linda S. Barnes: Blood Deserts Are a Global Health Challenge
-
Jun 15, 2026, 18:24Celebrating Emna Gouider’s Renewed Leadership at WFH Congress 2026 – WFH
-
Jun 15, 2026, 18:14Anastasia Conti: Connecting Celebrating and Advancing Hematology at EHA 2026
-
Jun 15, 2026, 18:01Eric Mwenda: Honoring Blood Donors and Partnerships in Tanzania
-
Jun 15, 2026, 17:37Vincent Elsey: The Ethereal Anatomy of a Broken Vessel
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management
-
Jun 15, 2026, 16:20New Therapeutic Strategies Targeting Iron Metabolism
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle